Related Experiment Video

Updated: Aug 16, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

Growth hormone treatment of idiopathic short stature: clinical studies

Raymond L Hintz1

  • 1Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA. hintz@stanford.edu

Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society
|July 26, 2005
PubMed

Insights

Growth hormone (GH) treatment for idiopathic short stature in children is now FDA-approved, simplifying selection beyond provocative tests. This allows for better treatment decisions based on height deficit and potential for normal adult height.

Area of Science:

  • Pediatrics
  • Endocrinology

Background:

  • Traditional selection for growth hormone (GH) treatment in short-statured children relied on provocative testing.
  • Provocative testing is often unphysiologic, difficult to administer, and potentially dangerous.

Purpose of the Study:

  • To evaluate the effectiveness and safety of GH treatment for idiopathic short stature in children.
  • To inform treatment decisions based on degree of short stature and potential for normal adult height.

Main Methods:

  • Analysis of studies involving GH therapy in children with idiopathic short stature.
  • Assessment of height outcomes and safety profiles.

Main Results:

  • GH therapy can effectively and safely promote height outcomes within the normal adult range.
  • Variability in height response to GH treatment was observed, presenting clinical challenges.

Conclusions:

  • FDA approval of GH for idiopathic short stature offers a rational treatment option.
  • Treatment decisions can now be guided by height deficit and potential for normal adult height, moving beyond problematic provocative tests.

More Related Videos

Treatment of Ligament Constructs with Exercise-conditioned Serum: A Translational Tissue Engineering Model08:03

Treatment of Ligament Constructs with Exercise-conditioned Serum: A Translational Tissue Engineering Model

Published on: June 11, 2017

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...